Abstract
Abstract. Putri RRA, Manullang RH, Andrianto R, Salsabila S, Izdihar RS, Setyawan AD. 2026. Review: Typhonium flagelliforme as a source of functional ingredients and medicinal leads with evidence, safety, and research priorities. Asian J Trop Biotechnol 23 (1): c230106. https://doi.org/10.13057/biotek/c230106. Typhonium flagelliforme (Araceae), commonly known as rodent tuber or keladi tikus, is widely promoted in Southeast Asia as a medicinal plant and is increasingly discussed as a prospective food or functional ingredient. This critical narrative review draws on 151 sources, including 35 publications explicitly focused on T. flagelliforme or rodent tuber, and evaluates its identity, ecology, cultivation, traditional uses, proposed food applications, phytochemistry, pharmacology, safety, and translational readiness. The strongest evidence concerns anticancer-related activity: crude extracts and fractions have produced cytotoxic, antiproliferative, invasion-inhibitory, apoptosis-associated, or antitumor responses in cell and animal models. However, no defensible pooled anticancer IC₅₀ range could be calculated because plant organs, extracts, cell models, exposure periods, assays, and controls were heterogeneous. One ethanol-tuber antioxidant study reported a 2,2-diphenyl-1-picrylhydrazyl (DPPH) IC₅₀ of 74.359 µg/mL, but this chemical assay does not demonstrate therapeutic efficacy. Immunomodulatory, antimicrobial, and hepatic findings remain preliminary, and no controlled clinical evidence demonstrates efficacy for cancer or any other human disease. Evidence for routine food use is substantially weaker and lacks adequate data on nutrient composition, calcium oxalate, validated processing, palatability, and long-term intake. Significant priorities include voucher-based authentication, validated extract fingerprints, bioassay-guided fractionation, normal-cell selectivity, repeated-dose toxicology, pharmacokinetics, and product-specific regulatory evaluation. Without this foundation, the plant's established preclinical promise cannot translate responsibly to human applications.